<?xml version="1.0" encoding="UTF-8"?>
<ref id="B161-vaccines-08-00224">
 <label>161.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Di Giambenedetto</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Ciccullo</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Borghetti</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Gambassi</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Landi</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Visconti</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Zileri Dal Verme</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Bernabei</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Tamburrini</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Cauda</surname>
    <given-names>R.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection</article-title>
  <source>J. Med. Virol.</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1002/jmv.25897</pub-id>
 </element-citation>
</ref>
